Agenda Announced for 2025 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease
November 14, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association today announced the agenda including tracks and Chairs for the 2025 MDA Clinical & Scientific Conference being held...
Muscular Dystrophy Association Shines a Spotlight on National Family Caregivers Awareness Month in November
October 31, 2024 09:12 ET
|
Muscular Dystrophy Association
New York, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) proudly highlights National Family Caregivers Awareness Month this November. MDA's month-long campaign emphasizes...
Muscular Dystrophy Association Launches Holiday Retail Campaign in Thousands of Retail Locations Nationwide
October 30, 2024 09:35 ET
|
Muscular Dystrophy Association
New York, Oct. 30, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today kicked off its largest annual Holiday Retail Campaign, spanning thousands of retail locations nationwide...
Muscular Dystrophy Association Advocate Rhys Hoskins Honored by his Peers with Two 2024 Players Choice Awards
October 28, 2024 08:32 ET
|
Muscular Dystrophy Association
New York, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association and the Players Trust, the charitable arm of the Major League Baseball Players Association, are thrilled to announce...
MDA Kickstart Program Receives FDA Rare Pediatric Disease Designation and Orphan Drug Designation for Congenital Myasthenic Syndrome
October 24, 2024 12:50 ET
|
Muscular Dystrophy Association
New York, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) proudly announces that its groundbreaking MDA Kickstart program has received both an FDA Rare Pediatric Disease...
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
October 11, 2024 07:00 ET
|
NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
October 11, 2024 01:00 ET
|
NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
October 08, 2024 07:30 ET
|
Biogen Inc.
Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to...
MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development
September 09, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
September 04, 2024 07:30 ET
|
Biogen Inc.
Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational...